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For decades, classical cytogenetic techniques that yielded a karyotype were the mainstay for 
identifying and characterizing the causes of certain genetic syndromes and birth defects. The 
capacity to identify chromosome anomalies expanded in the late 1980s and the 1990s with 
the development and maturation of fluorescent in situ hybridization (FISH) techniques to 
interrogate submicroscopic regions of the chromosomes for deletions or duplications. 
Beyond karyotypes and FISH, new technologies—chromosomal microarrays and next 
generation DNA sequencing—have markedly increased the number of birth defects and 
genetic syndromes that now have a known cause. These new testing techniques that can 
unambiguously confirm a diagnosis—as occurred previously, for example, with FISH for 
22q11.2 deletions—will increase the specificity and sensitivity for classifying birth defects 
and improve prevalence estimates. Although these testing techniques improve the resolution 
of analysis of smaller and more complex chromosome and DNA anomalies, their 
interpretation can be problematic, particularly when the test results are of unknown 
significance. Broader usage of new prenatal screening technologies, such as testing for 
chromosome and DNA anomalies in cell-free fetal DNA, will likely impact prevalence 
estimates of certain birth defects included in surveillance systems. These new advancements 
in genetic testing can create challenges for birth defects surveillance and research programs 
in learning how to abstract, interpret, classify, store, and incorporate new findings into 
surveillance systems, as well as categorizing the data in epidemiological studies. Birth 
defects research and surveillance programs must be mindful of these new challenges and 
thoughtful in addressing them.
TRADITIONAL CYTOGENETICS: HISTORICAL BACKGROUND
Advances in the field of cytogenetics over the years have yielded an increased understanding 
of the causes of numerous syndromes, diseases, and structural birth defects. These advances 
have arisen based on the desire to understand human chromosomes and the information that 
they contain. Although the interest in chromosomes waxed and waned during the late 1800s 
and early 1900s, chromosomes have been studied in ever-increasingly detailed and revealing 
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ways since the mid-1900s. The first recognizable drawings of human chromosomes were 
published in 1882 by Walther Flemming (Flemming, 1882), but it took until 1956 to realize 
that 46 was the correct number of chromosomes in human cells (Tjio and Levan, 1956). The 
subsequent development of banded karyotype analysis allowed for the identification of the 
aneuploidies responsible for Turner (monosomy X), Klinefelter (47,XXY), Down (trisomy 
21), Edwards (trisomy 18), and Patau (trisomy 13) syndromes (Ford et al., 1959; Jacobs and 
Strongs, 1959; Lejeune et al., 1959; Edwards et al., 1960; Patau et al., 1960), as well as 
chromosomal translocations involved in cancer cytogenetics such as the Philadelphia 
chromosome (Nowell and Hungerford, 1960). Analysis of material from spontaneous 
abortions showed that over half of miscarriages are due to aneuploidies (Kajii et al., 1973; 
Boué et al., 1975; Carr and Gedeon, 1978). As cytogenetic analysis became commonplace, 
families of individuals affected by syndromes or birth defects could have cytogenetic testing 
whereby the results could refine the possibility of recurrence, thus informing future 
reproductive choices. Initially, all cytogenetic tests were done postnatally on cells derived 
from tissues such as blood, biopsies, bone marrow, and products of conception. Beginning 
around the late 1960s, the reproductive decision process could include an existing pregnancy 
because it became possible to diagnose chromosomal aberrations prenatally using the 
technique of amniocentesis and subsequent karyotype (Steele and Breg, 1966; Nadler, 
1968).
GENETIC TESTING BEYOND TRADITIONAL CYTOGENETICS
Chromosome analysis expanded beyond banded karyotypes with the advent of fluorescent in 
situ hybridization (FISH) to diagnose submicroscopic chromosomal deletions and 
duplications (Langer et al., 1981; Langer-Safer et al., 1982), which together with polymerase 
chain reaction (PCR) (Saiki et al., 1985), became the mainstay technologies of modern day 
cytogenetics. However, recent genetic testing has begun to move beyond traditional 
cytogenetics. The American College of Medical Genetics and Genomics published 
guidelines in 2007 (Shaffer et al., 2007) regarding the clinical use of chromosomal 
microarrays (CMA) (an umbrella term encompassing both array-based comparative genomic 
hybridization [aCGH], which detects copy number variation, and single nucleotide 
polymorphism arrays), which has several advantages over FISH and traditional cytogenetic 
karyotyping. There is improved laboratory expediency with CMA as it allows for the 
simultaneous interrogation of hundreds of thousands of loci for potential duplication or 
deletion, which is not possible with FISH. aCGH has a resolution of 1 kilobase (Kb) while 
FISH can only detect changes approximately 100 Kb or larger and traditional karyotypes 
typically have a resolution of 5000 Kb or larger (Miller et al., 2010; Evangelidou et al., 
2013). This improved resolution with aCGH facilitates the detection of many structural 
abnormalities that would have been missed using only a traditional karyotype; for example, 
in a recent study, aCGH detected losses and gains in approximately 20% of apparently 
balanced translocations previously analyzed by karyotype (Manning et al., 2010). Based on 
the advantages of aCGH over traditional karyotypes, Miller et al. (2010) recommended that 
CMA become the first-tier genetic test for patients with unexplained developmental 
disabilities, intellectual disabilities, autism spectrum disorder, or multiple congenital 
anomalies, while continuing to use karyotype and FISH first for individuals with suspected 
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trisomies and for those with a history of recurrent miscarriage. A recent study concurred that 
CMA should be the first-tier test, but presented evidence that traditional cytogenetic analysis 
remains useful in some cases for detecting chromosomal mosaicism and characterizing 
structural chromosome rearrangements (Bi et al., 2013). Beginning in 2006, CMA has been 
performed prenatally with cells derived from amniocentesis or chorionic villus sampling 
(CVS) (reviewed in Evangelidou et al., 2013), although current recommendations are for it 
to be offered only as an optional screening tool with validation requiring karyotype and 
FISH analyses (American College of Obstetrics and Gynecology, 2009). In addition to 
CMA, another new technology changing the field of genetic diagnosis is next generation 
DNA sequencing (NGS), a massively parallel shotgun sequencing technique. NGS allows 
for the sequencing of whole genomes or whole exomes (the portion of the genome that 
codes for proteins) at a fraction of the cost with greatly increased coverage depth compared 
with first generation sequencing (Wetterstrand, 2013).
Perhaps the most significant recent development in genetic diagnosis, at least prenatally, is 
based on finding cell-free fetal DNA (cffDNA) in maternal blood in quantities substantial 
enough to be used to screen for aneuploidies. Although the discovery of cffDNA occurred in 
1997 (Lo et al., 1997), it took the next ten years to develop the methods that would reliably 
differentiate between cffDNA and maternal cell-free DNA (Lo and Chiu, 2007, 2008), as 
fetal DNA represents just 10% of the cell-free DNA found in maternal plasma (Nygren et 
al., 2010). Numerous studies have used NGS to validate the use of cffDNA for prenatal 
detection of trisomy 13, 18, 21, and sex chromosome aneuploidies. The best results to date 
have shown a nearly 100% detection rate of trisomy 21 with a false-positive rate of less than 
1%, and detection rates for trisomies 13 and 18 are now approaching those levels; however, 
it must be noted that these validation studies have been done in high risk pregnancies, not as 
population-based screenings (reviewed in Langlois et al., 2013). Because of this caveat and 
the varying detection rates, cffDNA analysis is currently being offered only as a screening 
test rather than as a diagnostic test, and results indicative of an aneuploidy require validation 
through karyotype analysis of cells collected by means of amniocentesis or CVS (Gregg et 
al., 2013). Further down the road is the prenatal use of NGS and cffDNA to obtain whole 
genome and exome fetal DNA sequences for prenatal diagnosis of a myriad of genetic 
conditions; however, this technology is still in the research phase and not yet clinically 
available (Kitzman et al., 2012).
INCORPORATING NEW GENETIC TESTING RESULTS INTO 
SURVEILLANCE ACTIVITIES: HOW MUCH INFORMATION IS TOO MUCH?
With each technological advancement in genetic testing, there have been challenges in 
learning how to interpret and incorporate the newly generated findings into clinical practice, 
as well as into surveillance activities and epidemiological studies. First and foremost, for 
those working in surveillance programs, it is not inherently obvious how to interpret the 
terminology used by laboratories to describe test results. Beyond standard karyotype 
nomenclature, which by itself has some degree of technical complexity, the terminology to 
describe FISH and CMA test results (ISCN Committee, 2013) might be even more 
perplexing to some who work in clinical medicine and population surveillance. Laboratory 
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reports are often long and packed with detail describing the results, as well as the technology 
that was used to perform the tests. It can be challenging to determine what components of 
the report need to be abstracted and included in a surveillance record; surveillance programs 
will need to make decisions regarding the extent of data that will be collected and train those 
who report or abstract test results according to surveillance protocols. Another related issue 
is how to classify actual test results. For years, surveillance systems captured only two types 
of cytogenetic tests: prenatal and postnatal chromosome analysis. With the current 
assortment of new tests and even newer ones on the horizon, it is not clear to many 
programs how to classify FISH, CMA, and now NGS test results because they do not 
exactly fit under the previous rubric. Surveillance programs will likely need to expand their 
diagnostic test categories to capture data that are generated by new advances in testing.
INCORPORATING NEW GENETIC TESTING RESULTS INTO 
SURVEILLANCE ACTIVITIES: WHAT IS TRULY SIGNIFICANT?
Technology has now progressed to the point where a single test has the potential to produce 
much more data than are needed to answer the question originally posed, with some results 
being of unknown clinical significance. For example, in CMA testing, the reports of results 
may include CNVs (copy number variations—duplications or deletions in chromosomal 
segments) that are known to be pathologic or benign, as well as CNVs of unknown 
significance (not known whether they are benign and represent normal variation in the 
population, or they are truly pathologic and related to the person’s phenotype, i.e., birth 
defects and other features and medical problems). In some cases, the indication for 
performing the CMA test might have been for a phenotype that would have otherwise not 
been eligible for inclusion as a case in a birth defects surveillance system (e.g., seizures, low 
muscle tone); in such cases when the CMA test shows only CNVs of unknown significance, 
surveillance programs will need guidance whether or not to include these cases as true 
abnormalities. Even if a CNV is clearly known to be pathologic, the surveillance program 
might not be certain whether the presence of the CNV is related to the infant’s phenotype or 
is just a coincidental finding. This abundance of uncertain data makes it challenging, not 
only in deciding whether to include certain cases in a surveillance system, but also how to 
classify cases with uncertain data into categories for epidemiological studies. In addition, 
when pathologic CNVs and particular phenotypes are clearly related, the fact that most 
surveillance programs will encounter very few cases with each particular CNV makes it 
problematic to evaluate these small numbers of cases in epidemiological and outcomes 
studies; only by combining resources and expertise from multiple surveillance programs 
might some of these classification and analysis issues be resolved.
Although there are several complexities for surveillance programs in dealing with results 
from CMA tests, these are potentially orders of magnitude larger when it comes to NGS 
results. Sequencing a person’s exome or whole genome typically yields thousands of genetic 
sequence variants that need to be sorted through to determine if they are pathologic, benign, 
or of unknown significance, and among those potentially pathologic, which variants might 
or might not be responsible for the person’s phenotype. With both CMA and NGS tests, 
CNVs or variants that are of unknown significance today could be determined in the future 
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to be either pathologic or benign; it will be a challenge for surveillance programs if they 
choose to update and reclassify cases based on new information or include cases that were 
initially excluded because of uncertain data. Finally, large amounts of data are generated by 
CMA or NGS tests, so there may be limitations on how much data could be recorded or 
stored long-term in a surveillance database. Learning how to incorporate data from these 
new tests within the confines of birth defect research and surveillance presents significant 
challenges to the field that will take time to resolve.
THE IMPACTS OF NEW GENETIC TESTING ON PREVALENCE
Could the newer diagnostic testing technologies impact the reported birth prevalence of 
certain birth defects that are ascertained by surveillance programs? In a word—possibly. As 
a result of CMA and NGS testing, there will definitely be a shift from cases of unknown 
etiology to those that have a known genetic cause. This was observed previously with the 
incorporation of FISH testing into clinical practice; for example, in population surveillance, 
cases with 22q11.2 deletion are now frequently identified (Tézenas Du Montcel et al., 1996; 
Devriendt et al., 1998; Goodship et al., 1998; Botto et al., 2003) when before the availability 
of FISH to diagnose this submicroscopic deletion, many such cases included in surveillance 
systems could have been of unknown etiology, clinically diagnosed as something else, or not 
ascertained at all (Emanuel et al., 1998; Katzman et al., 2005). Therefore, reported rates will 
likely increase for specific conditions that are diagnosed with expanded technologies. 
However, use of other technologies, such as cffDNA analysis might cause the reported birth 
prevalence of certain conditions to decrease. Several studies have reported that if 
surveillance programs fail to account for cases of trisomy 13, 18, or 21 that are stillborn or 
identified by prenatal diagnosis and electively terminated, there are significant 
underestimations of the prevalence (Stoll et al., 1998; Forrester and Merz, 1999, 2002a,b; 
Parker et al., 2003; Siffel et al., 2004; Crider et al., 2008). These under-ascertained cases 
typically occurred in women offered prenatal diagnosis because of their age, abnormal 
serum screening test results, or abnormal ultrasound findings. Because cffDNA analysis for 
prenatal cytogenetic abnormalities will likely be offered to the broader population, there is 
potential that this newer testing technology will further impact the estimated prevalence of 
aneuploidy disorders such as Down syndrome, as well as other conditions with cytogenetic 
abnormalities. Therefore, surveillance programs that do not account for cases identified by 
prenatal diagnosis may further underestimate population rates.
THE ROAD AHEAD: HOW TO AVOID FALLING OFF THE CLIFF
In summary, whether performed prenatally or postnatally, the myriad information available 
from CMA, NGS, and cffDNA is changing how genetic syndromes and birth defects are 
diagnosed and classified. The new genetic testing technologies are making significant 
contributions toward understanding the causes of birth defects and developmental 
disabilities. Birth defects surveillance programs need to keep abreast of these new diagnostic 
tests; develop the means to incorporate new genetic data for case ascertainment, 
classification, and etiological studies; and be cognizant of the potential effects on birth 
prevalence estimates. Finally, programs should also remain forward-thinking; if history is 
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any indicator, newer and even more exciting genetic testing opportunities are probably just 
around the corner.
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